Cytomegalovirus immediate-early 1-derived peptide–HLA complex (CMV IE-1 pMHC)

The Cytomegalovirus (CMV) immediate-early 1 (IE-1)-derived peptide–HLA complex is a specific antigenic target formed by the presentation of CMV IE-1 protein fragments on the cell surface via Human Leukocyte Antigen (HLA) molecules (PMID: 12134021). As IE-1 is one of the first proteins expressed during the viral lytic cycle, this complex serves as a critical signal for the immune system to identify and destroy infected cells (PMID: 10799895). In clinical practice, this complex is a primary target for adoptive T-cell therapies aimed at controlling CMV reactivation in immunocompromised patients, such as hematopoietic stem cell transplant recipients (PMID: 25653438). Additionally, the presence of CMV IE-1 antigens in certain malignancies, most notably glioblastoma multiforme, has positioned this pMHC complex as a promising target for cancer immunotherapy, including TCR-engineered T cells and TCR-like antibodies (PMID: 12036955, PMID: 22948177). Therapeutic intervention typically involves the use of cytotoxic T lymphocytes (CTLs) that recognize the complex with high specificity, thereby minimizing damage to healthy, non-infected tissues. However, challenges such as viral-mediated downregulation of MHC molecules and potential cross-reactivity with host peptides remain significant considerations in drug development (PMID: 15140986).

Other names

CMV IE1 peptide-MHC complexIE1-derived peptide-HLA-A*02:01 complexHCMV IE1 pMHCCytomegalovirus IE-1-derived peptide–HLA peptide-MHC complex

The mechanism of action involves the specific recognition of the IE-1 peptide presented within the groove of an HLA molecule by the T-cell receptor (TCR) of a CD8+ T cell, triggering cytotoxic activity and apoptosis of the target cell (PMID: 12134021, PMID: 10799895).